-
Recent Posts
Recent Comments
Archives
- October 2012
- December 2011
- November 2011
- September 2011
- March 2011
- December 2010
- November 2010
- September 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- November 2009
- October 2009
- September 2009
- July 2009
- June 2009
- February 2009
- January 2009
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- May 2008
- April 2008
- March 2008
- February 2008
- January 2008
- December 2007
- November 2007
- October 2007
- September 2007
- August 2007
- July 2007
- June 2007
- May 2007
- February 2007
- December 2006
- November 2006
- October 2006
- August 2006
- April 2006
- March 2006
- December 2005
- November 2005
- July 2005
- March 2005
- February 2005
- January 2005
- December 2004
- November 2004
- October 2004
- September 2004
- August 2004
Categories
Meta
Monthly Archives: February 2009
Metabolic acidosis and zonisamide
The FDA has issued a warning that zonisamide may be associated with metabolic acidosis in patients with with predisposing conditions or therapies. The young appear more at risk. Further info here. The FDA recommends that healthcare professionals measure serum bicarbonate … Continue reading
Posted in FDA
Comments Off
Efalizumab (Raptiva): Recommendation to suspend marketing authorisation
The MHRA reports on an EMEA decision on Efalizumab (Raptiva): The European Medicines Agency has completed a review of efalizumab (Raptiva) after concerns about its safety. The Agency’s Committee for Medicinal Products for Human Use (CHMP) has concluded that the … Continue reading
Drug Safety Update February 2009
Drug Safety Update by the MHRA includes this month: Tibolone (Livial): increased risk of breast cancer recurrence Non-steroidal anti-inflammatory drugs: cardiovascular risk Toremifene (Fareston): risk of QT prolongation Methylphenidate: new guidance for use in treatment of ADHD Correction: Temsirolimus—severe hypersensitivity … Continue reading
Posted in MHRA
Comments Off